These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
67 related items for PubMed ID: 24963647
1. Investigation of genotoxicity in acromegaly from peripheral blood lymphocyte cultures using a micronucleus assay. Unal OK, Cinkilic N, Gul OO, Cander S, Vatan O, Ersoy C, Yilmaz D, Tuncel E. J Clin Endocrinol Metab; 2014 Oct; 99(10):E2060-6. PubMed ID: 24963647 [Abstract] [Full Text] [Related]
4. Assessment of disease activity in treated acromegalic patients using a sensitive GH assay: should we achieve strict normal GH levels for a biochemical cure? Costa AC, Rossi A, Martinelli CE, Machado HR, Moreira AC. J Clin Endocrinol Metab; 2002 Jul; 87(7):3142-7. PubMed ID: 12107214 [Abstract] [Full Text] [Related]
8. Usefulness of different biochemical markers of the insulin-like growth factor (IGF) family in diagnosing growth hormone excess and deficiency in adults. Marzullo P, Di Somma C, Pratt KL, Khosravi J, Diamandis A, Lombardi G, Colao A, Rosenfeld RG. J Clin Endocrinol Metab; 2001 Jul; 86(7):3001-8. PubMed ID: 11443159 [Abstract] [Full Text] [Related]
9. Evaluation of disease status with sensitive measures of growth hormone secretion in 60 postoperative patients with acromegaly. Freda PU, Post KD, Powell JS, Wardlaw SL. J Clin Endocrinol Metab; 1998 Nov; 83(11):3808-16. PubMed ID: 9814451 [Abstract] [Full Text] [Related]
10. Octreotide as primary therapy for acromegaly. Newman CB, Melmed S, George A, Torigian D, Duhaney M, Snyder P, Young W, Klibanski A, Molitch ME, Gagel R, Sheeler L, Cook D, Malarkey W, Jackson I, Vance ML, Barkan A, Frohman L, Kleinberg DL. J Clin Endocrinol Metab; 1998 Sep; 83(9):3034-40. PubMed ID: 9745397 [Abstract] [Full Text] [Related]
12. The effects of long-term growth hormone and insulin-like growth factor-1 exposure on the development of cardiovascular, cerebrovascular and metabolic co-morbidities in treated patients with acromegaly. Jayasena CN, Comninos AN, Clarke H, Donaldson M, Meeran K, Dhillo WS. Clin Endocrinol (Oxf); 2011 Aug; 75(2):220-5. PubMed ID: 21521288 [Abstract] [Full Text] [Related]
13. Ultrasound measurement of median and ulnar nerve cross-sectional area in acromegaly. Tagliafico A, Resmini E, Nizzo R, Bianchi F, Minuto F, Ferone D, Martinoli C. J Clin Endocrinol Metab; 2008 Mar; 93(3):905-9. PubMed ID: 18073306 [Abstract] [Full Text] [Related]
14. Discordant nadir GH after oral glucose and IGF-I levels on treated acromegaly: refining the biochemical markers of mild disease activity. Elias PC, Lugao HB, Pereira MC, Machado HR, Castro Md, Moreira AC. Horm Metab Res; 2010 Jan; 42(1):50-5. PubMed ID: 19798623 [Abstract] [Full Text] [Related]
17. Clinical indicators of biochemical remission in acromegaly: does incomplete disease control always mean therapeutic failure? Damjanovic SS, Neskovic AN, Petakov MS, Popovic V, Macut D, Vukojevic P, Joksimovic MM. Clin Endocrinol (Oxf); 2005 Apr; 62(4):410-7. PubMed ID: 15807870 [Abstract] [Full Text] [Related]
18. GH and IGF-I excess control contributes to blood pressure control: results of an observational, retrospective, multicentre study in 105 hypertensive acromegalic patients on hypertensive treatment. Colao A, Terzolo M, Bondanelli M, Galderisi M, Vitale G, Reimondo G, Ambrosio MR, Pivonello R, Lombardi G, Angeli A, degli Uberti EC. Clin Endocrinol (Oxf); 2008 Oct; 69(4):613-20. PubMed ID: 18410555 [Abstract] [Full Text] [Related]